Jubilant Pharmova Limited has announced its financial results for the first quarter of FY25, showcasing significant growth across various segments. The company has maintained its growth momentum, achieved EBITDA margin expansion, and reduced its net debt/EBITDA ratio. Let’s delve into the key highlights and segmental performance. Financial Highlights Particulars Q1FY24 Q1FY25 YoY change Total Income …